Emmaus Life Sciences Inc

Company Profile

Emmaus Life Sciences Inc had its IPO on under the ticker symbol EMMA.

The company operates in the Healthcare sector and Biotechnology industry. Emmaus Life Sciences Inc has a staff strength of 54 employees.

Stock update

Shares of Emmaus Life Sciences Inc opened at $0.15 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $0.15 - $0.15, and closed at $0.15.

This is a 0% increase from the previous day's closing price.

A total volume of 1 shares were traded at the close of the day’s session.

In the last one week, shares of Emmaus Life Sciences Inc have slipped by -0.66%.

Emmaus Life Sciences Inc's Key Ratios

Emmaus Life Sciences Inc has a market cap of $17.16 million, indicating a price to book ratio of 0 and a price to sales ratio of 1.0565.

In the last 12-months Emmaus Life Sciences Inc’s revenue was $21.91 million with a gross profit of $17.30 million and an EBITDA of $-4636000. The EBITDA ratio measures Emmaus Life Sciences Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Emmaus Life Sciences Inc’s operating margin was -21.38% while its return on assets stood at -5.83% with a return of equity of 0%.

In Q1, Emmaus Life Sciences Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 108.8%.

Emmaus Life Sciences Inc’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

Its diluted EPS in the last 12-months stands at $-0.25 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Emmaus Life Sciences Inc’s profitability.

Emmaus Life Sciences Inc stock is trading at a EV to sales ratio of 3.1916 and a EV to EBITDA ratio of -3.6964. Its price to sales ratio in the trailing 12-months stood at 1.0565.

Emmaus Life Sciences Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$48.95 million

Total Liabilities

$57.86 million

Operating Cash Flow

$0

Capital Expenditure

$6000

Dividend Payout Ratio

0%

Emmaus Life Sciences Inc ended 2024 with $48.95 million in total assets and $0 in total liabilities. Its intangible assets were valued at $48.95 million while shareholder equity stood at $-35953000.00.

Emmaus Life Sciences Inc ended 2024 with $0 in deferred long-term liabilities, $57.86 million in other current liabilities, 51000.00 in common stock, $-255905000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $1.77 million and cash and short-term investments were $1.77 million. The company’s total short-term debt was $26,171,000 while long-term debt stood at $1.00 million.

Emmaus Life Sciences Inc’s total current assets stands at $7.42 million while long-term investments were $38.53 million and short-term investments were $0. Its net receivables were $2.20 million compared to accounts payable of $4.73 million and inventory worth $2.22 million.

In 2024, Emmaus Life Sciences Inc's operating cash flow was $0 while its capital expenditure stood at $6000.

Comparatively, Emmaus Life Sciences Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$0.15

52-Week High

$0.6

52-Week Low

$0.071

Analyst Target Price

$

Emmaus Life Sciences Inc stock is currently trading at $0.15 per share. It touched a 52-week high of $0.6 and a 52-week low of $0.6. Analysts tracking the stock have a 12-month average target price of $.

Its 50-day moving average was $0.2 and 200-day moving average was $0.31 The short ratio stood at 0.48 indicating a short percent outstanding of 0%.

Around 3798% of the company’s stock are held by insiders while 0.8% are held by institutions.